The Sleeping Beauty (SB) transposon system can insert sequences into mammalian chromosomes, supporting long-term expression of both reporter and therapeutic genes. Hematopoietic progenitor cells (HPCs) are an ideal therapeutic gene transfer target as they are used in therapy for a variety of hematologic and metabolic conditions. As successful SB-mediated gene transfer into human CD34+ HPCs has been reported by several laboratories, we sought to extend these studies to the introduction of a therapeutic gene conferring resistance to methotrexate (MTX), potentially providing a chemoprotective effect after engraftment. SB-mediated transposition of hematopoietic progenitors, using a transposon encoding an L22Y variant dihydrofolate reductase fused to green fluorescent protein, conferred resistance to methotrexate and dipyridamole, a nucleoside transport inhibitor that tightens MTX selection conditions, as assessed by in vitro hematopoietic colony formation. Transposition of individual transgenes was confirmed by sequence analysis of transposon–chromosome junctions recovered by linear amplification-mediated PCR. These studies demonstrate the potential of SB-mediated transposition of HPCs for expression of drug resistance genes for selective and chemoprotective applications.
Get full access to this article
View all access options for this article.
References
1.
IvicsZ, HackettPB, PlasterkRH, et al.Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 1997; 91:501–510.
2.
IzsvákZ, IvicsZ, and PlasterkRH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol, 2000; 302:93–102.
3.
LuoG, IvicsZ, IzsvákZ, et al.Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. Proc Natl Acad Sci U S A, 1998; 95:10769–10773.
4.
MontiniE, HeldPK, NollM, et al.In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther, 2002; 6:759–769.
5.
BelurLR, FrandsenJL, DupuyAJ, et al.Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. Mol Ther, 2003; 8:501–507.
6.
HackettPB, LargaespadaDA, and CooperLJN. A transposon and transposase system for human application. Mol Ther, 2010; 18:674–683.
7.
MátésL, ChuahMKL, BelayE, et al.Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet, 2009; 41:753–761.
8.
SumiyoshiT, HoltNG, HollisRP, et al.Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther, 2009; 20:1607–1626.
9.
XueX, HuangX, NodlandSE, et al.Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood, 2009; 114:1319–1330.
10.
SjeklochaLM, WongPY, BelcherJD, VercellottiGM, SteerCJ. β-Globin Sleeping Beauty transposon reduces red blood cell sickling in a patient-derived CD34(+)-based in vitro model. PLoS One., 2013; 8(11):e80403.
11.
SjeklochaLM, ParkC-W, WongPY, et al.Erythroid-specific expression of β-globin from Sleeping Beauty-transduced human hematopoietic progenitor cells. PLoS One, 2011; 6:e29110.
12.
BlakelyR, and BenkovicS. Folates and Pterins. John Wiley & Sons, New York. 1984.
13.
SchornagelJH, and McVieJG. The clinical pharmacology of methotrexate. Cancer Treat Rev, 1983; 10:53–75.
14.
BertinoJR. Karnofsky Memorial Lecture: ode to methotrexate. J Clin Oncol, 1993; 11:5–14.
15.
SirotnakFM, and MoccioDM. Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse. Cancer Res, 1980; 40:1230–1234.
16.
RiveraGK, EvansWE, KalwinskyDK, et al.Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. J Clin Oncol, 1985; 3:201–206.
17.
BelurLR, JamesRI, MayC, et al.Methotrexate preconditioning allows sufficient engraftment to confer drug resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity. J Pharmacol Exp Ther, 2005; 314:668–674.
18.
McIvorRS. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application. Bone Marrow Transpl, 1996; 18(Suppl 3):S50–S54.
19.
MorrisJA, and McIvorRS. Saturation mutagenesis at dihydrofolate reductase codons 22 and 31: a variety of amino acid substitutions conferring methotrexate resistance. Biochem Pharmacol, 1994; 47:1207–1220.
20.
JamesRI, MayC, VagtMD, et al.Transgenic mice expressing the Tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate. Exp Hematol, 1997; 25:1286–1295.
21.
LiMX, BanerjeeD, ZhaoSC, et al.Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood, 1994; 83:3403–3408.
22.
GoriJL, Podetz-PedersenK, SwansonD, et al.Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase. J Pharmacol Exp Ther, 2007; 322:989–997.
23.
PersonsDA, AllayJA, BonifacinoA, et al.Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood, 2004; 103:796–803.
24.
AllayJA, PersonsDA, GalipeauJ, et al.In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med, 1998; 4:1136–1143.
25.
LewisVA, BassoL, BlakeN, et al.Human nerve growth factor receptor and cytosine deaminase fusion genes. Hum Gene Ther, 2003; 14:1009–1016.
26.
OhlfestJR, FrandsenJL, FritzS, et al.Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood, 2005; 105:2691–2698.
27.
ClarkKJ, CarlsonDF, FosterLK, et al.Enzymatic engineering of the porcine genome with transposons and recombinases. BMC Biotechnol, 2007; 7:42.
28.
MoriarityBS, RahrmannEP, BeckmannDA, et al.Simple and efficient methods for enrichment and isolation of endonuclease modified cells. PLoS One, 2014; 9:e96114.
29.
EavesCJ, and LambieK. Atlas of Human Hematopoietic Colonies. Stem Cell Technologies, Inc., Vancouver, BC, Canada. 1995.
30.
SchmidtM, SchwarzwaelderK, BartholomaeC, et al.High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods, 2007; 4:1051–1057.
31.
HylandKA, OlsonER, ClarkKJ, et al.Sleeping Beauty-mediated correction of Fanconi anemia type C. J Gene Med, 2011; 13:462–469.
32.
AltschulSF, MaddenTL, SchäfferAA, et al.Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res, 1997; 25:3389–3402.
33.
TerstappenLW, HuangS, SaffordM, et al.Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38– progenitor cells. Blood, 1991; 77:1218–1227.
34.
IshikawaF, YasukawaM, LyonsB, et al.Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain(null) mice. Blood, 2005; 106:1565–1573.
35.
WarlickCA, SweeneyCL, and McIvorRS. Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition. Biochem Pharmacol, 2000; 59:141–151.
36.
SurP, MatsuoY, OtaniT, et al.Reversal of methotrexate-induced folate pool depletion by thymidine in a human leukemia cell line in vitro. Tumori, 1993; 79:433–438.
37.
NelsonJA, and DrakeS. Potentiation of methotrexate toxicity by dipyridamole. Cancer Res, 1984; 44:2493–2496.
38.
SjeklochaL, ChenY, DalyMC, et al.β-Globin matrix attachment region improves stable genomic expression of the Sleeping Beauty transposon. J Cell Biochem, 2011; 112:2361–2375.
39.
FlasshoveM, BanerjeeD, LeonardJP, et al.Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Hum Gene Ther, 1998; 9:63–71.
40.
TakebeN, XuL-C, MacKenzieKL, et al.Methotrexate selection of long-term culture initiating cells following transduction of CD34+ cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther, 2002; 9:308–320.
41.
NienhuisAW, DunbarCE, and SorrentinoBP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther, 2006; 13:1031–1049.
42.
YantSR, WuX, HuangY, et al.High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol, 2005; 25:2085–2094.
43.
FieldA-C, VinkC, GabrielR, et al.Comparison of lentiviral and Sleeping Beauty mediated αβ T cell receptor gene transfer. PLoS One, 2013; 8:e68201.
44.
TurchianoG, LatellaMC, Gogol-DöringA, et al.Genomic analysis of Sleeping Beauty transposon integration in human somatic cells. PLoS One, 2014; 9:e112712.
45.
AmbrosiA, GladIK, PellinD, et al.Estimated comparative integration hotspots identify different behaviors of retroviral gene transfer vectors. PLoS Comput Biol, 2011; 7:e1002292.
46.
SinghH, HulsH, KebriaeiP, et al.A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev, 2014; 257:181–190.
47.
GeurtsAM, YangY, ClarkKJ, et al.Gene transfer into genomes of human cells by the Sleeping Beauty transposon system. Mol Ther, 2003; 8:108–117.
48.
SweeneyCL, FrandsenJL, VerfaillieCM, et al.Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase. Cancer Res, 2003; 63:1304–1310.
49.
Budak-AlpdoganT, AlpdoganO, BanerjeeD, et al.Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Mol Ther, 2004; 10:574–584.
50.
ZhaoRC, McIvorRS, GriffinJD, et al.Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood, 1997; 90:4687–4698.
51.
AllayJA, GalipeauJ, BlakleyRL, et al.Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells, 1998; 16(Suppl 1):223–233.
52.
JonnalagaddaM, BrownCE, ChangW-C, et al.Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy. PLoS One, 2013; 8:e65519.
53.
CartierN, Hacein-Bey-AbinaS, BartholomaeCC, et al.Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 2009; 326:818–823.
54.
WilberA, FrandsenJL, LargaespadaDA, et al.RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. Mol Ther, 2006; 13:625–630.
